甲状腺转移作为结肠腺癌伴KRAS突变的首发表现:18F-FDG PET/CT的应用价值
本文报道一例74岁无症状女性,甲状腺细胞学提示恶性但来源不明,18F-FDG PET/CT揭示为Ⅳ期结肠腺癌伴KRAS突变及甲状腺、肺、肝多发转移。及时化疗后生存21个月。同期诊断甲状腺转移与原发性结肠腺癌极罕见,迄今仅报道5例,均行甲状腺手术,平均生存7个月。
要点
- 18F-FDG PET/CT有助于明确甲状腺恶性病变的来源,本例检出Ⅳ期结肠腺癌多发转移。
- 同期诊断甲状腺转移与结肠腺癌极罕见,迄今仅报道5例,均行甲状腺手术,平均生存7个月。
- 本例及时化疗后生存21个月。
核心结论
- 18F-FDG PET/CT在甲状腺细胞学提示恶性但来源不明时有助于明确原发肿瘤,本例检出Ⅳ期结肠腺癌伴KRAS突变及多发转移。
研究设计与样本
- 本文为病例报告,报道一例74岁无症状女性,甲状腺细胞学提示恶性但肿瘤来源不确定。
主要发现
- 18F-FDG PET/CT显示Ⅳ期结肠腺癌伴KRAS突变及甲状腺、肺、肝多发转移。
- 及时制定化疗方案后患者生存21个月。
- 同期诊断甲状腺转移与原发性结肠腺癌迄今仅报道5例,均行甲状腺手术,平均生存7个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The synchronous diagnosis of a thyroid metastasis and of the primary colon adenocarcinoma that produces it is very rare, with only 5 cases reported to date, all of them treated with thyroid surgery showing a mean survival of 7 months. An ¹⁸F-FDG PET/CT in an asymptomatic 74-year-old woman with a thyroid cytology suggestive of malignancy but uncertain about the origin of the tumor revealed an stage IV colon adenocarcinoma with KRAS mutation and multiple metastasis (thyroid, lung, and liver). A prompt therapeutic planning with chemotherapy allowed 21 months of survival.
引用
- Lecumberri B, López E, Coronado M, et al. Thyroid Metastasis as First Manifestation of a Colon Adenocarcinoma With KRAS Mutation: Usefulness of 18F-FDG PET/CT. Clin Nucl Med. 2017. PMID: 28872477. doi:10.1097/RLU.0000000000001776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。